Cargando…
Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review
Leucine-rich alpha⁃2 glycoprotein 1 (LRG1) is an important member of the leucine-rich repetitive sequence protein family. LRG1 was mainly involved in normal physiological activities of the nervous system, such as synapse formation, synapse growth, the development of nerve processes, neurotransmitter...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797156/ https://www.ncbi.nlm.nih.gov/pubmed/35095520 http://dx.doi.org/10.3389/fphar.2021.809225 |
_version_ | 1784641483673960448 |
---|---|
author | Zou, Yonghui Xu, Yi Chen, Xiaofeng Wu, Yaoqi Fu, Longsheng Lv, Yanni |
author_facet | Zou, Yonghui Xu, Yi Chen, Xiaofeng Wu, Yaoqi Fu, Longsheng Lv, Yanni |
author_sort | Zou, Yonghui |
collection | PubMed |
description | Leucine-rich alpha⁃2 glycoprotein 1 (LRG1) is an important member of the leucine-rich repetitive sequence protein family. LRG1 was mainly involved in normal physiological activities of the nervous system, such as synapse formation, synapse growth, the development of nerve processes, neurotransmitter transfer and release, and cell adhesion molecules or ligand-binding proteins. Also, LRG1 affected the development of respiratory diseases, hematological diseases, endocrine diseases, tumor diseases, eye diseases, cardiovascular diseases, rheumatic immune diseases, infectious diseases, etc. LRG1 was a newly discovered important upstream signaling molecule of transforming growth factor⁃β (TGF⁃β) that affected various pathological processes through the TGF⁃β signaling pathway. However, research on LRG1 and its involvement in the occurrence and development of diseases was still in its infancy and the current studies were mainly focused on proteomic detection and basic animal experimental reports. We could reasonably predict that LRG1 might act as a new direction and strategy for the treatment of many diseases. |
format | Online Article Text |
id | pubmed-8797156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87971562022-01-29 Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review Zou, Yonghui Xu, Yi Chen, Xiaofeng Wu, Yaoqi Fu, Longsheng Lv, Yanni Front Pharmacol Pharmacology Leucine-rich alpha⁃2 glycoprotein 1 (LRG1) is an important member of the leucine-rich repetitive sequence protein family. LRG1 was mainly involved in normal physiological activities of the nervous system, such as synapse formation, synapse growth, the development of nerve processes, neurotransmitter transfer and release, and cell adhesion molecules or ligand-binding proteins. Also, LRG1 affected the development of respiratory diseases, hematological diseases, endocrine diseases, tumor diseases, eye diseases, cardiovascular diseases, rheumatic immune diseases, infectious diseases, etc. LRG1 was a newly discovered important upstream signaling molecule of transforming growth factor⁃β (TGF⁃β) that affected various pathological processes through the TGF⁃β signaling pathway. However, research on LRG1 and its involvement in the occurrence and development of diseases was still in its infancy and the current studies were mainly focused on proteomic detection and basic animal experimental reports. We could reasonably predict that LRG1 might act as a new direction and strategy for the treatment of many diseases. Frontiers Media S.A. 2022-01-05 /pmc/articles/PMC8797156/ /pubmed/35095520 http://dx.doi.org/10.3389/fphar.2021.809225 Text en Copyright © 2022 Zou, Xu, Chen, Wu, Fu and Lv. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zou, Yonghui Xu, Yi Chen, Xiaofeng Wu, Yaoqi Fu, Longsheng Lv, Yanni Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review |
title | Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review |
title_full | Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review |
title_fullStr | Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review |
title_full_unstemmed | Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review |
title_short | Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review |
title_sort | research progress on leucine-rich alpha-2 glycoprotein 1: a review |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797156/ https://www.ncbi.nlm.nih.gov/pubmed/35095520 http://dx.doi.org/10.3389/fphar.2021.809225 |
work_keys_str_mv | AT zouyonghui researchprogressonleucinerichalpha2glycoprotein1areview AT xuyi researchprogressonleucinerichalpha2glycoprotein1areview AT chenxiaofeng researchprogressonleucinerichalpha2glycoprotein1areview AT wuyaoqi researchprogressonleucinerichalpha2glycoprotein1areview AT fulongsheng researchprogressonleucinerichalpha2glycoprotein1areview AT lvyanni researchprogressonleucinerichalpha2glycoprotein1areview |